Previously, such chemically synthesized polypeptide products were excluded from the regulatory transition, so subsequent-entry products referencing these drugs would not be eligible for biosimilars or interchangeable product approval. Such products would also not be eligible for generic drug development.
This week, the House of Representatives approved a $1.4 trillion spending package, and included in the bill is a newly added provision, reported BioWorld, that will allow chemically synthesized polypeptides to be included in the upcoming March 2020 transition of some products to regulation as biologics and biosimilars rather than as drugs and follow-ons.
Previously, such chemically synthesized polypeptide products were excluded from the regulatory transition, so subsequent-entry products referencing these drugs would not be eligible for biosimilars or interchangeable product approval. Such products would also not be eligible for generic drug development.
In a statement, the FDA’s deputy commissioner for policy, legislation, and international affairs, Anna Abram, and director of the Center for Drug Evaluation and Research, Janet Woodcock, MD, voiced support for the change.
The previous exclusion of chemically synthesized polypeptides from the regulatory rollover, said Abram and Woodcock, “could hurt potential competition because it means that if a developer were to chemically synthesize a copy of a protein product (e.g., an insulin copy), the product would not be able to come to market through the abbreviated biosimilar or interchangeable pathway, but instead would have to submit a new drug application, which could be much more resource-intensive.”
Removing the exclusion, said the regulators, will help patients get access to cheaper drugs sooner—including chemically synthesized insulins—through a more efficient regulatory pathway. They also said that the change will allow for innovation in manufacturing processes, which could have benefits in terms of efficiency.
However, detractors note that the change could have impacts on intellectual property protections for these products, given the fact that biologics are subject to lengthier patent protection than are small-molecule products. Public Citizen, for one, said in a statement that the provision could have the result of “forcing consumers to wait years for affordable medicine.”
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.